|
EQS-News: MediClin AG
/ Key word(s): Preliminary Results
Offenburg, February 29, 2024
MEDICLIN presents preliminary figures for the 2023 financial year
MEDICLIN achieved group sales of EUR 730.1 million in the 2023 financial year (previous year: EUR 704.7 million). At EUR 12.7 million, the group operating result was EUR 6.8 million below the previous year's figure (2022: EUR 19.5 million) due to a one-off effect. The one-off effect relates to the impairment of goodwill for three facilities in the acute segment, which had a negative impact of EUR 33.1 million on earnings.
With a growth rate of 3.6%, group sales were within the forecast published in the 2022 annual report. The group operating result of EUR 12.7 million is within the new forecast of EUR 10.0 to 15.0 million published in January 2024, which was updated due to the one-off effect.
Tino Fritz, CFO of MEDICLIN, comments: "Despite all the challenges, 2023 was an operationally successful financial year. We achieved an occupancy rate of at least 80% in all quarters. Capacity utilisation, the decisive factor for our factor for our economic success, is gradually normalising to the levels seen before the outbreak of the coronavirus pandemic." and adds: "This means that we are full of confidence for the business outlook for 2024."
Development in the segments and the nursing care business area In the post-acute segment, sales increased by 4.6% to €451.2 million (2022: €431.2 million). At EUR 52.7 million, the segment operating result was EUR 31.5 million higher than in the same period of the previous year (2022: EUR 21.2 million). The acute segment generated sales of EUR 254.0 million, which was an increase of 0.5% (2022: EUR 252.7 million). The segment operating result of EUR -39.9 million was burdened by impairment losses on goodwill for three facilities with a negative one-off effect of EUR 33.1 million. In the previous year, the segment operating result totalled EUR -4.4 million. Sales in the nursing care business area, which is allocated to the other activities and reconciliation segment, rose from € 18.7 million in the previous year to € 21.3 million in 2023. The segment operating result for the business division amounted to 0.2 million euros in 2023 after -1.0 million euros in 2022. Employees and investments The number of employees (calculated in full-time equivalents) in the 2023 reporting year, was on average 7,016 (previous year: 7,025 full-time equivalents). MEDICLIN invested in the future of the Group in 2023 with gross investments amounting EUR 38.8 million (previous year: EUR 28.5 million).
The Annual Report 2023 will be available from 26 March 2024 at www.mediclin.de in German and English. You are welcome to subscribe to the IR newsletter here to receive regular updates on all topics relevant to investors. For more information: MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Germany Investor Relations Ender Gülcan Phone +49 781/488-326 ender.guelcan@mediclin.de About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.
MEDICLIN ─ a company of the Asklepios Group
29.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | MediClin AG |
| Okenstraße 27 | |
| 77652 Offenburg | |
| Germany | |
| Phone: | +49 (0)781 488-326 |
| Fax: | +49 (0)781 488-184 |
| E-mail: | ender.guelcan@mediclin.de |
| Internet: | www.mediclin.de |
| ISIN: | DE0006595101 |
| WKN: | 659510 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1848629 |
| End of News | EQS News Service |
|
|
1848629 29.02.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
